ArticleERJ open research2025
Influence of age in the assessment of therapeutic response in patients with pulmonary arterial hypertension.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In patients with pulmonary arterial hypertension (PAH), current European guidelines recommend achieving a low-risk profile, primarily based on World Health Organization functional class (WHO-FC), 6-min walk distance (6MWD) and natriuretic peptides. However, these noninvasive parameters are influenced by age. We investigated the impact of age on treatment response and evaluated the prognostic role of haemodynamic-based risk assessments. Methods: Treatment-naïve PAH patients from a single-centre registry were included, stratified by age. Clinical and functional measures and haemodynamics were assessed at baseline and after initial PAH-targeted therapy. Prognostic discrimination was performed using noninvasive (European Society of Cardiology/European Respiratory Society 4-strata, REVEAL Lite 2) and haemodynamic-based risk models (including a purely haemodynamic - RHC - risk tool) with Cox regression and C-statistics. Results: 794 PAH patients were enrolled. Elderly individuals exhibited worse WHO-FC, higher levels of natriuretic peptides and shorter 6MWD, despite lower right ventricular (RV) afterload, likely due to comorbidities and worse RV function. Improvement of WHO-FC, levels of natriuretic peptides and 6MWD is lower in the elderly, despite comparable haemodynamic changes across the age groups. In older patients, noninvasive risk tools overestimated RHC risk tool severity and demonstrated a reduced prognostic accuracy. In patients aged >65 years reaching a low-risk haemodynamic profile, noninvasive risk tools were of no added prognostic value. Conversely, haemodynamics provided independent prognostic information in younger patients. Conclusions: Haemodynamics is less influenced by age than noninvasive risk assessment and is of added prognostic value to noninvasive assessment in younger patients. Achieving a low-risk haemodynamic profile can be a valid therapeutic target when noninvasive criteria are not met in patients aged >65 years.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.